

S2 Table. Detailed characteristics of patients with bulky node involvement

No.	Age (yr)	Sex	T category	N category	Largest node (cm, location)	Nodal disease station (PR/II/EI/IN)	RT dose (primary, Gy)	RT dose (gross node, Gy)	RT dose (elective, Gy)	CRx	Failure pattern	DFI (mo)
1	54	F	1	N1a	2.5, IN	-/-/-/+	60.4	60.4	50.4	FC	Local	19.2
2	74	F	2	N1a	2.4, II	+/+/-/-	55.0	55.0	50.0	FM	None	43.6
3	56	F	3	N1a	5.5, IN	+/+/-/+	59.4	59.4	41.4	FM	Regional (IN)	20.4
4	62	M	3	N1a	3.1, IN	-/+/-/+	59.4	59.4	50.4	FM	None	49.9
5	69	F	3	N1c	2.9, IN	-/+/>+/>+	54.0	64.8	54.0	XP	Local & distant	10.9
6	71	M	2	N1c	5.2, IN	+/>+/>+/>+	54.0	54.0	44.0	FM	LR (EI, IN) & DM	15.7
7	35	F	2	N1a	2.4, II	+/>+/>-/>-	59.4	59.4	50.4	FM	None	99.7

CRx, chemotherapy; DFI, disease-free interval; DM, distant metastasis; EI, external iliac; FC, 5-FU+carboplatin; FM, 5-FU+mitomycin C; II, internal iliac; IN, inguinal; LR, loco-regional; PR, perirectal; RT, radiotherapy; XP, capecitabine+cisplatin.